Key facts
- This page summarizes Nathan Joel Berman's Form 4 filing for Exactus, Inc. (PLSH).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 06 Jul 2021, 17:28.
Nathan Joel Berman - 30 Jun 2021 Form 4 Insider Report for Exactus, Inc. (PLSH)
- Reporting relationship
- CONTROLLER & PRIN ACTNG OFCR
- Issuer ticker
- PLSH
- Reported as of
- 30 Jun 2021
- Net transaction value
- $0
- Reporting owner signature
- /s/ Nathan Berman
Source evidence
Original filing metadata and source links for verification.
3 source fields
Reporting owner
1 detail
Filing notes and source
Key filing fact
Nathan Joel Berman filed Form 4 for Exactus, Inc. (PLSH) on 06 Jul 2021.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
PLSH
transaction
Common Stock
Award
- Transaction value
- Shares
- +496,957
- Change %
- Price
- Shares after
- 496,957
- Date
- 30 Jun 2021
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
PLSH
transaction
Derivative
Stock Options (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +496,957
- Change %
- Price
- $0.000000
- Shares after
- 496,957
- Date
- 30 Jun 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 496,957
- Exercise price
- $0.1000
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The shares of common stock of the Issuer were acquired in exchange for shares of common stock of Panacea Life Sciences, Inc. ("Panacea"), in connection with the Securities Exchange Agreement dated June 30, 2021 by and among the Issuer, Panacea and the shareholders of Panacea.
Footnote F2
One-half of the stock options vest upon the effective date of a 1:28 reverse stock split of the Issuer's common stock, and the remainder vest on June 30, 2022, subject to continued employment with the Issuer.